medigraphic.com
ISSN 0016-3813 (Print)

2016, Number S2

<< Back Next >>

Gac Med Mex 2016; 152 (S2)

Comparison of the effectiveness of hematopoietic cell mobilization with chemotherapy and filgrastim versus filgrastim alone for autologous transplant in patients with lymphoma

Gutiérrez-Aguirre CH, De la Garza-Salazar F, Cantú-Rodríguez O, González-Llano Ó, Jaime-Pérez JC, Mancias-Guerra C, García-Sepúlveda R, Salazar-Riojas R, Gómez-Almaguer D

Language: Spanish
References: 27
Page: 57-65
PDF size: 119.64 Kb.


ABSTRACT

Introduction: Autologous hematopoietic stem cell transplantation is the treatment of choice for high-risk Hodgkin’s lymphoma and non-Hodgkin’s lymphoma. Objective: Compare the capacity to mobilize CD34+ cells for autologous hematopoietic stem cell transplantation using schemes with chemotherapy and without chemotherapy plus filgrastim in patients diagnosed with Hodgkin’s lymphoma or non-Hodgkin’s lymphoma. Material and methods: The clinical records of patients with Hodgkin’s lymphoma or non-Hodgkin’s lymphoma who received an autologous hematopoietic stem cell transplant were analyzed retrospectively. Filgrastim alone or in combination with chemotherapy was used as mobilization scheme. Cell harvesting was classified as adequate when › 2 × 106 cells/kg were collected. Results: Forty-seven patients (Hodgkin’s lymphoma, 24; non-Hodgkin’s lymphoma, 23) were included. Comparing groups of Hodgkin’s lymphoma mobilized with chemotherapy (15 patients) and without chemotherapy (nine patients), one apheresis procedure was sufficient in 73 and 44% of patients, respectively (p = 0.04), the average of CD34 + cells/kg collected was 11 x 106 and 3 x 106, respectively (p = 0.017), and the collection was adequate in 100 and 55.6% of cases, respectively (p = 0.014). Comparing the groups of non-Hodgkin’s lymphoma mobilized with chemotherapy (six patients) and without chemotherapy (17 patients), one apheresis procedure was sufficient in 33 and 65% of patients, respectively (p = 0.26), the average of CD34+ cells/kg was 3.56 x 106 and 3.41 x 106, respectively (p = 0.47), and collection was adequate in 66.6 and 59% of cases, respectively (p = 0.37). Conclusion: In Hodgkin’s lymphoma patients, mobilization schemes with chemotherapy were more effective considering the number of cells collected, the number of apheresis required, and the percentage of successful cell collections. In non-Hodgkin’s lymphoma patients, there were no significant differences between the two groups.


REFERENCES

  1. Van Den Neste E, Casasnovas O, André M, et al. Classical Hodgkin’s lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica. 2013;98:1185-95.

  2. Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:498-505.

  3. Manko J, Walter-Croneck A, Jawniak D, et al. A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization. Pharmacol Rep. 2014;66:239-42.

  4. Eichenauer D, Engert A, Dreyling M. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi55-8.

  5. Coiffier B. Treatment of diffuse large B-cell lymphoma. Curr Hematol Rep. 2005;4:7-14.

  6. Vassilakopoulos TP, Angelopoulou MK. Advanced and relapsed/refractory Hodgkin lymphoma: what has been achieved during the last 50 years. Semin Hematol. 2013;50:4-14.

  7. Ayala E. Hematopoietic cell transplantation for B-cell lymphoma: an update. Cancer Control. 2012;19:175-86.

  8. Ramchandren R. Advances in the treatment of relapsed or refractory Hodgkin’s lymphoma. Oncologist. 2012;17:367-76.

  9. Ayala E, Tomblyn M. Hematopoietic cell transplantation for lymphomas. Cancer Control. 2011;18:246-57.

  10. Holmberg L, Maloney DG. The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma. J Natl Compr Canc Netw. 2011;9:1060-71.

  11. Giralt S, Costa L, Schriber J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014;20:295-308.

  12. Stiff P, Gingrich R, Luger S, et al. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin’s disease or non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2000;26:471-81.

  13. Hopman RK, DiPersio JF. Advances in stem cell mobilization. Blood Rev. 2014;28:31-40.

  14. Rossi G, Skert C, Morello E, et al. PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G‐CSF mobilization. Hematol Oncol. 2015;33:125-32.

  15. Xia W, Ma CKK, Reid C, et al. Factors determining PBSC mobilization efficiency and nonmobilization following ICE with or without rituximab (R‐ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation. J Clin Apher. 2014;29:322-30

  16. Suzuya H, Watanabe T, Nakagawa R, et al. Factors associated with granulocyte colony‐stimulating factor‐induced peripheral blood stem cell yield in healthy donors. Vox Sang. 2005;89:229-35.

  17. Donmez A, Yilmaz F, Gokmen N, Tombuloglu M. Risk factors for a poor hematopoietic stem cell mobilization. Transfus Apher Sci. 2013;49:485-8.

  18. Sung AD, Grima DT, Bernard LM, et al. Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone. Bone Marrow Transplant. 2013;48:1444-9.

  19. Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica. 2007;92:35-41.

  20. Castagna L, Magagnoli M, Balzarotti M, et al. Tandem high‐dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin’s lymphoma: a monocenter prospective study. Am J Hematol. 2007;82:122-7.

  21. McQuaker I, Haynes A, Stainer C, Anderson S, Russell N. Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate‐dose cyclophosphamide. Br J Haematol. 1997;98:228-33.

  22. Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011;118:3419-25.

  23. Mollee P, Pereira D, Nagy T, et al. Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma. Bone Marrow Transplant. 2002;30:273-8.

  24. Varmavuo V, Rimpiläinen J, Kuitunen H, et al. Engraftment and outcome after autologous stem cell transplantation in plerixafor‐mobilized non‐ Hodgkin’s lymphoma patients. Transfusion. 2014;54:1243-50.

  25. Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I. ESHAP+ fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin’s lymphoma: a single institution result of 127 patients. Bone Marrow Transplant. 2006;37:277-82.

  26. Zinzani P. Ifosfamide, epirubicin and etoposide (IEV) in non-Hodgkin’s lymphoma and Hodgkin’s disease: the Italian experience. Ann Oncol. 2003;14(Suppl 1):i43-i5.

  27. Vela-Ojeda J, Tripp-Villanueva F, Montiel-Cervantes L, et al. Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization. Bone Marrow Transplant. 2000;25:1141-6.




2020     |     www.medigraphic.com